Quick Answer
Amphastar Pharmaceuticals, Inc. reported R&D Expense of $85.84 million for fiscal year 2025.
Amphastar Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $85.84M | +16.1% |
| 2024 | $73.91M | +0.2% |
| 2023 | $73.74M | -1.4% |
| 2022 | $74.77M | +22.7% |
| 2021 | $60.93M | -9.4% |
| 2020 | $67.23M | -2.4% |
| 2019 | $68.85M | +19.6% |
| 2018 | $57.56M | +32.3% |
| 2017 | $43.50M | +4.8% |
| 2016 | $41.52M | +11.4% |
| 2015 | $37.27M | +29.1% |
| 2014 | $28.87M | -12.6% |
| 2013 | $33.02M | +6.0% |
| 2012 | $31.16M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $22.35M | +6.1% | +11.3% |
| June 30, 2025 | $20.08M | +13.8% | -0.1% |
| March 31, 2025 | $20.10M | +17.9% | -4.7% |
| September 30, 2024 | $21.08M | +26.5% | +19.4% |
| June 30, 2024 | $17.65M | +4.8% | +3.6% |
| March 31, 2024 | $17.04M | -14.0% | +2.3% |
| September 30, 2023 | $16.66M | -10.0% | -1.1% |
| June 30, 2023 | $16.84M | -26.1% | -15.0% |
- Amphastar Pharmaceuticals, Inc. showed an increase of +16.1% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2025 period, Amphastar Pharmaceuticals, Inc.’s r&d expense has grown by 175.5% (from $31.16 million to $85.84 million).
- The most recent figure is from Amphastar Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: